MA-WATERS-CORPORATION
31.3.2022 14:02:14 CEST | Business Wire | Press release
Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system , the most sensitive and compact benchtop tandem mass spec in its class.i
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005189/en/
Waters’ newest high-performance mass spectrometer is up to 15X more sensitive for quantifying negatively ionizing compounds than its predecessorii and is 45% smaller and uses up to 50% less electricity and gas supply than other high-performance tandem quadrupole mass spectrometers available on the market.iii The Xevo TQ Absolute is designed to help pharmaceutical, food and beverage, and environmental analytical laboratories meet regulations requiring trace-level quantitative mass spectrometry analyses for a broad set of applications.
“The Xevo TQ Absolute is for laboratories looking for industry-leading quantitative sensitivity, accuracy, reproducibility, efficiency and sustainability,” said Jon Pratt, Waters Division Senior Vice President, Waters Corporation. “It offers more analytical firepower in a much smaller footprint than any other mass spec in its class, reaches exceptionally low limits of quantitation, and aids laboratory managers to best optimize their equipment utilization and analytical output.”
For optimal performance, Waters pairs the Xevo TQ Absolute mass spectrometer with Waters’ ACQUITY™ Premier UPLC System with MaxPeak™ HPS technology which eliminates non-specific adsorption of compounds containing phosphate and/or carboxylate groups and improves their recovery. Together, this integrated LC-MS/MS system is designed to drive the limits of quantitation to exceptionally low levels for many applications including:
- Quantifying regulated impurities in drug products
- Performing oligonucleotide bioanalytical assays
- Measuring concentrations of endogenous metabolites in large cohort clinical studies
- Quantifying residues and contaminants in food and environmental samples
- Measuring low-level drugs and toxicants in physiological matrices
- Detecting trace-level leachables from food packaging
The Xevo TQ Absolute incorporates thoughtful design features that enable consistent and reproducible analyses, allowing labs to maintain performance and uptime for longer periods in between routine cleaning and service intervals. This is achieved with new guidance on optimal probe positioning for both sensitivity and robustness and a source shield that helps minimize source contamination by the sample matrix or mobile phase salts.
The Xevo TQ Absolute is optimized for use with the waters_connect™ software platform and is also compatible with Waters MassLynx™ mass spectrometry software. For laboratories painstakingly reviewing the results from large numbers of samples, or those quantifying hundreds of small molecule components and contaminants in a single run, the MS Quan app on waters_connect and its unique Exception Focused Review (XFR) functionality, lets scientists review data in up to half the time it used to take themiv .
Worldwide customer shipments of the Xevo TQ Absolute are expected to commence in May.
Additional Resources
- Register here for our April 7 launch event
- Learn more about the Xevo TQ Absolute features and benefits
- Read the blog post Can Ever-Increasing Analytical Sensitivity and Sustainability Go Hand-in-Hand?
- Follow and connect with Waters via LinkedIn , Twitter , and Facebook
About Waters Corporation (www.waters.com )
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Xevo, ACQUITY, MaxPeak, MassLynx and waters_connect are trademarks of Waters Corporation.
______________________
i
Based on a comparison of the sensitivity and product specifications of currently available instruments on the market
ii
Waters Xevo TQ- XS
iii
Based on a comparison of product specifications for the Sciex 7500, Sciex 6500, Agilent 6495C and Thermo TSQ Altis
iv
Estimate based on time on task comparison of a batch of pesticides in a food safety analysis
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005189/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
